Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide.
miR-4732-5p in breast cancer. In addition, mRNA sequencing, bioinformatics analysis, Western blot and luciferase assays were performed to identify the target of miR-4732-5p. Overall, miR-4732-5p was significantly down-regulated in breast cancer tissues, especially in lymph node metastasis (LNM)-negative tissues, compared with adjacent normal tissues. However, it was more highly expressed in LNM-positive breast cancer tissues, compared with LNM-negative ones. Expression of miR-4732-5p was positively correlated with lymph node metastasis, larger tumour size, advanced clinical stage, high Ki-67 levels and poor prognosis. MiR-4732-5p promoted cell proliferation, migration and invasion in breast cancer. MiR-4732-5p directly targeted the 3′-UTR of tetraspanin 13 (TSPAN13) and suppressed TSPAN13 expression at the mRNA and protein levels. These results suggested that miR-4732-5p may serve as a tumour suppressor in the initiation of breast cancer, but as a tumour promoter in breast cancer progression by targeting TSPAN13.
K E Y W O R D S
breast cancer, metastasis, miR-4732-5p, proliferation, TSPAN13 the processes of invasion and metastasis in several types of cancer. 7, 8 MiR-10b and miR-335 were the first miRNAs to be reported as promoters or inhibitors of metastasis respectively. 9 In breast cancer, certain miRNAs have been associated with the invasionmetastasis cascade, including miR-10b, miR-21, miR-31, miR-373
and miR-520c. 10 MiR-4732-5p is a novel miRNA that has not been well studied in human cancers. In our previous study, miR-4732-5p was found to be down-regulated in breast cancerous nipple discharge compared with benign nipple discharge, supporting that it might serve as a potential tumour biomarker for breast cancer detection. 11 However, the expression and function of miR-4732-5p remain largely unknown.
Here, we provide evidence that miR-4732-5p was downregulated in lymph node metastasis (LNM)-negative breast cancer tissues; however, it was overexpressed in LNM-positive tissues.
MiR-4732-5p was positively associated with aggressive clinical parameters, poor prognosis and cell biological behaviours. Tetraspanin 13 (TSPAN13) was a direct target of miR-4732-5p. 
| MATERIAL SANDME THODS

| Tissuesamples
| Celltransfection
The miR-4732-5p mimics and negative control were obtained from GenePharma (Shanghai, China). MiRNA mimics are small, chemically modified, double-stranded RNA molecules that mimic endogenous mature miRNA molecules and widely used for short-term gain-offunction miRNA experiments. 12 MiRNA mimics and negative control transfection was carried out with the X-tremeGENE transfection reagent (Roche) according to the manufacturer's instructions. For stable expression of miR-4732-5p, cells were transfected with lentivirus miR-4732-5p-expressing vector LV3-hsa-miR-4732-5p or a negative control LV3NC (GenePharma, Shanghai, China), which expressed GFP (green fluorescent protein) as a marker. The expression of GFP was monitored under a fluorescence microscope. The transfected cells were screened with puromycin for the ones stably expressing miR-4732-5p.
| Cellproliferationassay
The proliferation ability of cells was monitored using the MTS 3-(4,
Cell Proliferation Assay; Promega, Madison, WI, USA), as previously described. 
| Colonyformationassay
Cells (300-500 per well) were seeded in six-well plates. After incubation for 2 weeks, colonies were fixed and stained.
| Migrationandinvasionassay
Cell migration capability was detected by using Transwell chambers (Corning, NY, USA) as previously described. 4 Transwell chambers pre-coated with the Matrigel matrix (BD Biosciences) were used for cell invasion assay.
| RNAextractionandquantitativereal-timePCR (qRT-PCR)
Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA, USA). cDNA synthesis and quantitative real-time PCR (qRT-PCR)
were performed with the All-in-One™ miRNA qRT-PCR Reagent Kit (GeneCopoeia) using a CFX™ 96 C1000 Real-Time machine, with the RNU6B small nuclear RNA as internal normalized reference. The miR-4732-5p and RNU6B primers were obtained from GeneCopoeia.
| mRNAsequencing
Total RNA from miR-4732-5p or negative control-transfected cells (n = 3 for each) was extracted using Trizol reagent (Invitrogen) and was subsequently used for removing the rRNAs using Ribo-Zero 
| Luciferaseassay
The wild-type (WT) TSPAN13 3′-UTR fragments or the mutant 
| Westernblot
Cells were harvested and protein extracts were obtained with lysis buffer. Equal amounts of protein were electrophoresed on 10% SDS-PAGE gels, and then transferred to PVDF membrane. After blocking, the membranes were incubated with anti-TSPAN13 
| Statisticalanalysis
Differences between two groups were analysed by Student's t test,
and ANOVA was used to find differences among three or more groups. Two-sided P < 0.05 was considered significant. The webtools miRpower, 14 BioProfiling 15, 16 and PrognoScan 17 were utilized to determine the prognostic value of miR-4732-5p and TSPAN13, respectively, in breast cancer using publicly available data.
| RE SULTS
| ExpressionofmiR-4732-5pinbreastcancer tissuesandcelllines
Expression of miR-4732-5p was detected in primary breast cancers and corresponding normal tissues. Among the 67 patients, 49 (73%)
cases showed significant lower expression of miR-4732-5p in breast cancer tissues compared with normal tissues (P = 0.0140, paired t test, Figure 1A ,B). Moreover, miR-4732-5p was found to be underexpressed in nine cancer cell lines compared to the non-tumourigenic cell line MCF10A (Figure 2A ). (Figure 2A ).
| AssociationbetweenmiR-4732-5pexpressionandclinicopathological parametersandprognosis
In addition, miR-4732-5p was found to be positively correlated with larger tumour size ( Figure 1G , one-way ANOVA, P = 0.0080),
high Ki-67 index ( Figure 1H , P = 0.0394) and advanced clinical stage ( Figure 1G , one-way ANOVA, P = 0.0016).
As breast cancer is rather heterogeneous, the relationship between miR-4732-5p expression and subtypes of breast cancer was further investigated. Our data showed that miR-4732-5p expression showed no significant difference among the four molecular subtypes The prognostic role of miR-4732-5p was determined by the miRpower database. 14 Our results showed that patients with high
F I G U R E 1 Expression of miR-4732-5p in breast cancer tissues and its association with clinicopathological parameters. (A-E) Overall, miR-
4732-5p was down-regulated in breast cancer tissues, compared with the corresponding normal tissues, especially in lymph node metastasis (LNM)-negative tissues (A-C). However, LNM-positive tissues displayed higher miR-4732-5p expression than lymph node metastasis (LNM)-negative tissues (A, D, E). N, normal tissues. (F-I) Expression of miR-4732-5p was positively correlated with lymph node metastasis (N stage, F), tumour size (T stage, G), Ki-67 expression (H) and clinical stage (I)
expression of miR-4732-5p (n = 526) had poorer survival than those with low expression of miR-4732-5p (n = 535, Figure 3A , HR = 2.03, P < 0.0001, TCGA dataset, all subtypes patients included). The median survival time of low expression group and high expression group was 148.53 and 113.63 months respectively. Interestingly, the miRpower database could also provide survival analysis in certain subtypes and we found that high expression of miR-4732-5p
was also associated with worse prognosis in ER+, PR+ and HER2+ patients ( Figure 3B-D) , suggesting that miR-4732-5p may be a risk prognostic factor independent of breast cancer subtypes.
| miR-4732-5ppromotedproliferation, migrationandinvasionofbreastcancercells
To investigate the functional effects of miR-4732-5p, we per- 
| Tetraspanin13(TSPAN13)wasidentifiedasa directtargetofmiR-4732-5p
To identify genes targeted by miR-4732-5p, we performed genomewide mRNA sequencing analysis using MDA-MB-231 cell line and selected down-regulated genes (fold change > 2 and P < 0.05) by miR-4732-5p transfection compared with negative control transfection ( Figure 4A ). Among 30 putative candidate genes, two genes (TSPAN13 and CDK18) contained putative binding sites of miR-4732-5p in their 3′-UTR regions, as revealed by the TargetScan database ( Figure 4B ). TSPAN13 was of particular interest in light of its reported roles in suppressing cancer cells progression. 18, 19 qRT-PCR and Western blot were performed to investigate whether miR-4732-5p altered TSPAN13 gene and protein expression. The F I G U R E 4 TSPAN13 was a direct target of miR-4732-5p and low expression of TSPAN13 was associated with poor prognosis of breast cancer patients. (A) MDA-MB-231 cells transfected with miR-4732-5p mimics (n = 3) or negative control (n = 3) were subjected to mRNA sequencing analysis to screen differentially expressed mRNAs. In total, 157 mRNAs were found to be up-regulated, whereas 170 mRNAs were down-regulated after miR-4732-5p mimics transfection (P < 0.05). Among them, 40 were up-regulated and 30 were down-regulated by more than twofold (fold change > 2, and P < 0.05) in the miR-4732-5p mimics group than the negative control group. (B) mRNA sequencing and TargetScan prediction indicated two potential target genes (TSPAN13 and CDK18) of miR-4732-5p. (C-E) miR-4732-5p could down-regulate mRNA and protein levels of TSPAN13. (F) TSPAN13 was a direct target of miR-4732-5p as revealed by luciferase assays. (G-H) Data from BioProfiling (G) and PrognoScan (H) showed that low expression of TSPAN13 predicted poor survival of breast cancer patients. *P < 0.05; **P < 0.01 mRNA and protein expression levels of TSPAN13 were significantly repressed in miR-4732-5p transfectants compared with negative control-transfected cells ( Figure 4C -E).
Next, luciferase assay was performed to determine whether TSPAN13 mRNA carried a target site for miR-4732-5p. The
TargetScan database predicted that one putative miR-4732-5p binding site existed in the 3′-UTR of the gene (position 151-157). Data showed that the luminescence intensity was significantly reduced by co-transfection with miR-4732-5p and the vector carrying the wild-type 3′-UTR of TSPAN13, rather than the mutant 3′-UTR with deleted target sites ( Figure 4F ).
Furthermore, the prognostic value of TSPAN13 was determined using publicly available data. As shown in BioProfiling, 15, 16 low expression of TSPAN13 predicted poor survival of breast cancer patients (GEO database: GSE250665, n = 507, P = 0.000546, Figure 4G ). Results from the PrognoScan database 17 showed that breast cancer patients with low expression of TSPAN13 had shorter survival time (GSE12276 dataset, n = 204, P = 0.001299, Figure 4H) than those with high TSPAN13 expression.
| D ISCUSS I ON
MiRNAs act as key regulators in cancer initiation and progression, including cell proliferation, apoptosis, differentiation, invasion, metastasis and drug resistance. 3, 4, 7, 10, 20 MiRNAs play roles as either tumour suppressors or oncogenes by negatively regulating their target genes. 7 For example, miR-489 inhibits breast cancer proliferation, metastasis and chemoresistance by suppressing SPIN1-mediated PI3K-Akt pathway. 3 , 21 Ma et al shows that Twist-induced expression of miR-10b initiated tumour invasion and metastasis in breast cancer. 22 In this study, miR-4732-5p was found to be down-regulated in breast cancer tissues compared with adjacent normal tissues.
However, increased expression of miR-4732-5p was found in cancer tissues with lymph node metastasis, larger tumour size, high Ki-67 index and advanced clinical stage, independent of cancer subtypes.
High expression of miR-4732-5p was associated with poor prognosis in breast cancer. MiR-4732-5p significantly promoted cell proliferation, colony formation, migration and invasion in breast cancer cells.
Mechanistically, TSPAN13 was identified as a direct target of miR-4732-5p and low expression of TSPAN13 was associated with poor survival of breast cancer patients.
Till now, reports on miR-4732-5p in human cancers were scarce.
Omura et al have reported that five miRNAs (miR-92b, 422a, 4732-5p, 4758-3p and 221) were highly expressed in gastric patients who relapsed than those who did not relapse and high expression of four miRNAs (miR-92b, 422a, 4732-5p and 4758-3p) indicated poor disease-free survival and overall survival in gastric cancer. 23 By using a miRNA microarray, Fukumoto et al found that miR-4732-5p was up-regulated in head and neck squamous cell carcinoma tissues compared with the corresponding normal tissues. 20 Previously we found that miR-4732-5p was down-regulated in nipple discharge from breast cancer patients compared to that in intraductal papilloma patients. 11 However, the detailed function and molecular mechanism of miR-4732-5p in breast cancer remain largely unknown. This is the first study to reveal that miR-4732-5p may promote breast cancer progression at least partially by directly targeting TSPAN13. It is also noted that miR-4732-5p was down-regulated in breast cancer tissues, compared with the corresponding normal tissues. We suspected that miR-4732-5p may act as a tumour suppressor in breast cancer initiation, however, an oncogene in tumour progression.
Previous studies have demonstrated certain genes could have distinct and opposing roles in the initiation as compared with the progression of human cancers. For example, STAT3 inhibits lung cancer initiation by maintaining pulmonary homeostasis, whereas it facilitates lung cancer progression by promoting cancer cell growth.
24
P38ɑ suppresses inflammation-associated epithelial damage and tumourigenesis but contributes to the proliferation and survival of colon cancer cells. 25 In breast cancer, TGFβ inhibits cell growth at early stages of carcinogenesis, but acts as an aggressive oncogene in more advanced malignant stages. 26 We comment that the "dual role"
of miR-4732-5p in breast cancer needs further investigation.
TSPAN13 (also known as NET-6) belongs to the tetraspanin superfamily, which has been implicated in a range of biological processes, including differentiation, motility, proliferation and metastasis. 27 The TSPAN13 gene is located on chromosome 7p21.1
and encodes a 204 amino acid protein with a predicted molecular weight of 24 kDa. 
